PSA levels at 6, 12, and 24 weeks post-randomization correlate with 96-month survival in prostate cancer
Low PSA at 24 weeks predicts longer survival in prostate cancer
This post-hoc analysis of five phase 3 trials in 7129 patients with prostate cancer found that 96-month overall survival varied by metastati…
Men with prostate cancer who hit a PSA level of 0.2 ng/mL or less within 24 weeks of starting treatment are far more likely to survive at le…
Enzalutamide Monotherapy Shows Higher Survival and Metastasis-Free Rates Versus Leuprolide in High-Risk Biochemical Recurrence
Enzalutamide shows better outcomes than leuprolide for high risk prostate cancer recurrence
This Phase 3 randomized controlled trial evaluated enzalutamide monotherapy versus leuprolide alone in patients with high-risk biochemical r…
Men with high-risk prostate cancer recurrence lived longer and spread less cancer when taking enzalutamide alone instead of leuprolide alone…
Deutenzalutamide improves rPFS in mCRPC after abiraterone and docetaxel progression
New Pill Slows Advanced Prostate Cancer After Other Drugs Fail
A randomized phase III trial in 417 patients with metastatic castration-resistant prostate cancer after progression on or intolerance to abi…
A new daily pill slowed advanced prostate cancer progression by 42 percent in men whose disease grew despite standard hormone therapy and ch…